In this issue of Blood, Li et al(1) show that detection of leukemic stem cells (LSCs) may predict relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) better than classical measurable residual disease (MRD) by multiparameter flow cytometry (MFC).

Voso, M.t., Buccisano, F. (2022). AML: making residual disease more measurable. BLOOD, 140(5), 415-417 [10.1182/blood.2022017138].

AML: making residual disease more measurable

Voso, Maria Teresa;Buccisano, Francesco
2022

Abstract

In this issue of Blood, Li et al(1) show that detection of leukemic stem cells (LSCs) may predict relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) better than classical measurable residual disease (MRD) by multiparameter flow cytometry (MFC).
Pubblicato
Rilevanza internazionale
Editoriale
Esperti anonimi
Settore MED/15
English
Humans
Neoplasm, Residual
Prospective Studies
Leukemia, Myeloid, Acute
Neoplasm Recurrence, Local
Voso, M.t., Buccisano, F. (2022). AML: making residual disease more measurable. BLOOD, 140(5), 415-417 [10.1182/blood.2022017138].
Voso, Mt; Buccisano, F
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/307762
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact